• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

POLL: Which Recent Drug Pipeline Move is Most Exciting?


Click here to answer this week's poll.

Many drug treatments have made pipeline moves in the last few weeks. Which one do you think is the most exciting?

Apremilast (Otezla; Amgen) receiving FDA approval for all psoriasis severities
Secukinumab (Cosentyx; Novartis) FDA approval for pediatric patients with PsA
Tralokinumab-Idrm (Adbry; Leo Pharma) receives FDA approval for AD
Roflumilast Cream (ARQ-151; Arcutis Biotherapeutics) has NDA accepted by FDA for psoriasis treatment
Something Else
Related Videos
infectious disease
© 2024 MJH Life Sciences

All rights reserved.